SCHEMBL1280200

SCHEMBL1280200

CN(CSCCN)CC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BHMT Q93088 1/20 0.44
TDP1 Q9NUW8 3/20 0.33
HIF1A Q16665 1/20 0.33
MVD P53602 1/20 0.31
EYA2 O00167 1/20 0.30
APP P05067 1/20 0.30
ACE P12821 1/20 0.30
LMNA P02545 1/20 0.30
KMT2A Q03164 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1280281 0.80 BHMT (0.47) BHMTTDP1HIF1AMVDEYA2
SCHEMBL1280629 0.77 HSD17B10 (0.53) BHMTTDP1KMT2AHSD17B10
SCHEMBL1279809 0.76 BHMT (0.44) BHMTTDP1HIF1AMVDEYA2
SCHEMBL16608921 0.76 HSD17B10 (0.56) TDP1APPKMT2AHSD17B10
SCHEMBL1280642 0.74 BHMT (0.37) BHMTTDP1HIF1A
SCHEMBL1280078 0.73 BHMT (0.39) BHMTTDP1MVDEYA2APP
SCHEMBL1280303 0.73 BHMT (0.39) BHMTHIF1A
SCHEMBL1280251 0.72
SCHEMBL2560448 0.72
SCHEMBL11214853 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10065992-B2 Cyclosporin analogs ALLERGAN, INC. (US) 2018-09-04 US claimed
EP-2627664-B1 CYCLOSPORIN ANALOGS ALLERGAN INC (US) 2018-04-04 EP claimed
US-20170029469-A1 CYCLOSPORIN ANALOGS ALLERGAN, INC. 2017-02-02 US claimed
US-9493511-B2 Cyclosporin analogs ALLERGAN, INC. (US) 2016-11-15 US claimed
US-20150065433-A1 CYCLOSPORIN ANALOGS ALLERGAN, INC. (US) 2015-03-05 US claimed
EP-2627664-A1 CYCLOSPORIN ANALOGS Allergan, Inc. (US) 2013-08-21 EP claimed
WO-2012051194-A1 CYCLOSPORIN ANALOGS ALLERGAN, INC. (US) 2012-04-19 WO claimed
US-20120088734-A1 Cyclosporin Analogs ALLERGAN, INC. (US) 2012-04-12 US claimed
US-10065992-B2 Cyclosporin analogs ALLERGAN, INC. (US) 2018-09-04 US disclosed
EP-2627664-B1 CYCLOSPORIN ANALOGS ALLERGAN INC (US) 2018-04-04 EP disclosed
US-20170029469-A1 CYCLOSPORIN ANALOGS ALLERGAN, INC. 2017-02-02 US disclosed
US-9493511-B2 Cyclosporin analogs ALLERGAN, INC. (US) 2016-11-15 US disclosed
US-20150065433-A1 CYCLOSPORIN ANALOGS ALLERGAN, INC. (US) 2015-03-05 US disclosed
EP-2627664-A1 CYCLOSPORIN ANALOGS Allergan, Inc. (US) 2013-08-21 EP disclosed
WO-2012051194-A1 CYCLOSPORIN ANALOGS ALLERGAN, INC. (US) 2012-04-19 WO disclosed
US-20120088734-A1 Cyclosporin Analogs ALLERGAN, INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065433-A1 CYCLOSPORIN ANALOGS CHP1, TSLP, PPP3R1 BHMT 3906/4885TDP1 2386/4885HIF1A 3937/4885
US-10065992-B2 Cyclosporin analogs CHP1, TSLP, PPP3R1 BHMT 3906/4885TDP1 2386/4885HIF1A 3937/4885
US-20120088734-A1 Cyclosporin Analogs CHP1, TSLP, PPP3R1 BHMT 3906/4885TDP1 2386/4885HIF1A 3937/4885
US-20170029469-A1 CYCLOSPORIN ANALOGS CHP1, TSLP, PPP3R1 BHMT 3906/4885TDP1 2386/4885HIF1A 3937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.